Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers.

MIT Center for Biomedical Innovation, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139-4307, USA.
dressNature Reviews Drug Discovery (Impact Factor: 37.23). 05/2007; 6(4):287-93. DOI: 10.1038/nrd2251
Source: PubMed

ABSTRACT The potential to use biomarkers for identifying patients that are more likely to benefit or experience an adverse reaction in response to a given therapy, and thereby better match patients with therapies, is anticipated to have a major effect on both clinical practice and the development of new drugs and diagnostics. In this article, we consider current and emerging examples in which therapies are matched with specific patient population characteristics using clinical biomarkers - which we call stratified medicine - and discuss the implications of this approach to future product development strategies and market structures.

  • Value in Health 09/2013; 16(6):S39-S43. DOI:10.1016/j.jval.2013.06.003 · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The study of human brain networks with in vivo neuroimaging has given rise to the field of connectomics, furthered by advances in network science and graph theory informing our understanding of the topology and function of the healthy brain. Here our focus is on the disruption in neuropsychiatric disorders (pathoconnectomics) and how whole-brain computational models can help generate and predict the dynamical interactions and consequences of brain networks over many timescales. We review methods and emerging results that exhibit remarkable accuracy in mapping and predicting both spontaneous and task-based healthy network dynamics. This raises great expectations that whole-brain modeling and computational connectomics may provide an entry point for understanding brain disorders at a causal mechanistic level, and that computational neuropsychiatry can ultimately be leveraged to provide novel, more effective therapeutic interventions, e.g., through drug discovery and new targets for deep brain stimulation. VIDEO ABSTRACT: Copyright © 2014 Elsevier Inc. All rights reserved.
    Neuron 12/2014; 84(5):892-905. DOI:10.1016/j.neuron.2014.08.034 · 15.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The term “Individualized medicine” comprises approaches to influence the progression of a disease or its prevention and which are based on therapeutic, preventive and rehabilitation interventions and specifically developed on the basis of the individual genetic disposition of each patient. Recently developed technologies such as the genotyping of mutation and metabolites offer the opportunity for individualized medical treatment. In this article, challenges from the demand and the supply side in the health care sector and its future financing are discussed with regard to this development. Individualized medicine will probably lead to higher total cost for the health system which will only be accepted if evidence to show the benefit gain for patients can be presented. Therefore, any general conclusion about total cost or reimbursement of services in individualized medicine is not possible, but these services will have to be assessed in each single case for their cost and benefit effects. Finally, it is emphasized that a sufficient information base on both sides of the market and the willingness to bear the risk to change current treatment and organizational practice will be essential.
    08/2013; 9(1):45-54. DOI:10.1007/BF03320773

Full-text (2 Sources)

Available from
May 30, 2014